Teacher Retirement System of Texas Has $2.54 Million Stake in Moderna, Inc. (NASDAQ:MRNA)

Teacher Retirement System of Texas trimmed its position in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 11.7% during the first quarter, according to its most recent 13F filing with the SEC. The fund owned 89,496 shares of the company's stock after selling 11,886 shares during the period. Teacher Retirement System of Texas' holdings in Moderna were worth $2,537,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently bought and sold shares of the company. Norges Bank acquired a new position in shares of Moderna in the 4th quarter valued at $163,833,000. Voloridge Investment Management LLC lifted its stake in shares of Moderna by 335.6% in the 4th quarter. Voloridge Investment Management LLC now owns 2,590,831 shares of the company's stock valued at $107,727,000 after purchasing an additional 1,996,003 shares during the period. FMR LLC lifted its stake in shares of Moderna by 7.4% in the 4th quarter. FMR LLC now owns 18,664,634 shares of the company's stock valued at $776,075,000 after purchasing an additional 1,282,469 shares during the period. Pictet Asset Management Holding SA lifted its stake in shares of Moderna by 170.5% in the 4th quarter. Pictet Asset Management Holding SA now owns 1,766,398 shares of the company's stock valued at $73,447,000 after purchasing an additional 1,113,455 shares during the period. Finally, Invesco Ltd. lifted its stake in shares of Moderna by 24.3% in the 4th quarter. Invesco Ltd. now owns 5,006,462 shares of the company's stock valued at $208,169,000 after purchasing an additional 979,858 shares during the period. 75.33% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on the company. JPMorgan Chase & Co. cut their price target on Moderna from $33.00 to $26.00 and set an "underweight" rating on the stock in a research note on Thursday, May 22nd. Barclays reaffirmed an "equal weight" rating on shares of Moderna in a research note on Sunday. Cowen began coverage on Moderna in a research note on Sunday. They set a "hold" rating on the stock. Morgan Stanley dropped their price objective on Moderna from $39.00 to $32.00 and set an "equal weight" rating on the stock in a research note on Wednesday, April 9th. Finally, Evercore ISI dropped their price objective on Moderna from $50.00 to $32.00 and set an "in-line" rating on the stock in a research note on Friday, May 2nd. Four investment analysts have rated the stock with a sell rating, seventeen have assigned a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Moderna presently has an average rating of "Hold" and an average price target of $46.61.

Moderna Stock Performance

Moderna stock traded down $0.64 during midday trading on Friday, reaching $33.64. 6,916,105 shares of the company's stock were exchanged, compared to its average volume of 8,875,613. Moderna, Inc. has a 52 week low of $23.15 and a 52 week high of $127.20. The firm has a market cap of $13.01 billion, a price-to-earnings ratio of -3.85 and a beta of 1.84. The stock's 50-day simple moving average is $27.21 and its 200 day simple moving average is $31.09.

Moderna (NASDAQ:MRNA - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The company reported ($2.52) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($2.92) by $0.40. Moderna had a negative return on equity of 28.69% and a negative net margin of 105.67%. The company had revenue of $108.00 million during the quarter, compared to analysts' expectations of $130.35 million. During the same quarter in the previous year, the company posted ($3.07) earnings per share. The business's revenue was down 35.3% on a year-over-year basis. Research analysts forecast that Moderna, Inc. will post -9.61 earnings per share for the current year.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.